Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1 Children aged 1 to \<5 years on the day of inclusion~2. History of received 1 dose of SA14-14-2 vaccine 12-24 months prior to enrollment~3. In good general health at the time of inclusion~4. Provision of informed consent by the parent(s) or legal guardian(s)~Exclusion Criteria:~1. Receipt of blood or blood products in the past 3 months.~2. Acute febrile illness on the day of vaccination.( BT \> 38 C)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- a live attenuated chimeric JE vaccine (Type: EXPERIMENTAL): Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.

Based on this trial design, predict the completion outcome and termination type (if applicable).